News
New angiotensin studies in COVID-19 give more reassurance
May 6, 2020
A deluge of new data does not suggest harm with ACE inhibitors and angiotensin blockers in COVID-19 rates or outcomes.
News
Multisociety roadmap eyes restarting elective cardiac cases
May 6, 2020
A new consensus document provides guidance on the safe reintroduction of cardiovascular procedures and testing derailed by the COVID-19 pandemic.
News
Diastolic dysfunction is a common risk factor for cognitive decline
May 5, 2020
Proposed mechanisms for cognitive decline in patients with systolic dysfunction include low cardiac output, embolic infarctions, and hypoxic changes, among others.
![1]()
News
Adding mechanical to pharma prophylaxis does not cut DVT incidence
May 4, 2020
Does adding mechanical prophylaxis to pharmacological prophylaxis lower the incidence of deep-vein thrombosis (DVT)?
![1]()
News
Hydroxychloroquine-triggered QTc-interval prolongations mount in COVID-19 patients
May 4, 2020
Two single-center reports further documented the incidence of QTc-interval prolongations in COVID-19 patients treated with hydroxychloroquine.
News
Out-of-hospital cardiac arrests soar during COVID-19 in Italy
May 1, 2020
Four provinces in northern Italy report increases of various magnitudes, ranging from 18% to a stunning 187%.
News
New study of diabetes drug for COVID-19 raises eyebrows
May 1, 2020
Some question the safety of AstraZeneca’s just-launched DARE-19 study testing whether dapagliflozin will reduce adverse outcomes of COVID-19.
News
Yale’s COVID-19 inpatient protocol: Hydroxychloroquine plus/minus tocilizumab
April 30, 2020
Yale cardiologist offers lessons from “the haze of battle” on fighting COVID-19 with little evidence.
![1]()
News
Survey: Hydroxychloroquine use fairly common in COVID-19
April 29, 2020
Testing and preparedness have increased, but a return to normal life could take another 6 months.
News
SGLT2 inhibitor ertugliflozin shows no CV death or renal benefit
April 29, 2020
Merck reports topline results from ertugliflozin’s FDA-mandated cardiovascular outcomes trial.
